Complete Story
11/06/2012
SYNRIBO (omacetaxine mepesuccinate)
Now Approved for CML
Teva Oncology announced the FDA approval of SYNRIBO™ for Injection
for the treatment of adult patients with chronic or accelerated phase chronic
myeloid leukemia (CML) with resistance and/or intolerance to two or more
tyrosine kinase inhibitors (TKIs) READ MORE
< Back | Printer Friendly Page
